- ASSOCIATE PROFESSOR | Pathology
- ASSOCIATE PROFESSOR | Oncological Sciences
Cancer, Cancer Genetics, Tumorigenesis
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Genetics and Genomic Sciences [GGS]
BSc, Complutense University of Madrid, Spain
PhD, Autonoma University of Madrid, Spain
PostDoc, Cold Spring Harbor Laboratory, NY
Senior Fellow, Cold Spring Harbor Laboratory, NY
Assistant Professor of Pathology, Columbia University Medical School
Adjunct Faculty, Columbia University Medical School
Unprecedented amount of information has been gathered regarding cancer genomes. However, our ability to identify functions that are critical only for cancer cells is still limited. We have successfully pioneered the integration of the state-of-the-art genomics, functional studies and system biology methods to generate functional maps. This integrative analysis pinpoints key regulatory hubs that when perturbed compromise cancer cell viability. My research is an ambitious and systematic program that start from the identification of the regulatory networks of cancer cells, it continues with in depth molecular characterization of the hubs involved in their homeostasis and it finishes with the translation of our discoveries to the clinic. Our research has generated 15 peer-review publications in the last three years (primary research and collaborations) including high profile journals such as Cell, Nature, Cancer Cell and Genes & Dev. Furthermore, our comprehensive studies have initiated one clinical trial (NCT02066532) and another one is on the way. The specific interest of my group is normal mammary development, breast tumorigenesis and therapeutics. For the near future, we will expand our findings of RSF1, BIN3 and miR-424/503 as novel breast cancer genes (Cell-2014, Genes & Dev.-2014, MCB-2014, Cancer Cell-under review) as well as the evaluation of STAT3 and HDAC6 inhibition as novel targeted therapies (Genes & Dev-2015 and Cancer Res.-under review). In the farther future, we will follow up our recent studies identifying novel targets for triple negative breast cancers and investigating mechanistically the intersection of aging and cancer.
Research Open Positions
Updated October-2015 -We are looking for a molecular cell biologist with experience in breast cancer research. Previous experience in genetic manipulation of cellular models, basic biochemistry and mouse models of breast cancer will be beneficial. -Applicants must have shown research abilities and capabilities to perform collaborative project within a team, and possess good written and verbal communication skills in English. Applicants must have a Ph.D. and evidence of research productivity. Please send your C.V., contact information for two references, and a brief motivation letter including a summary of research experience to: Jose M. Silva; E-mail:firstname.lastname@example.org
Yu J, Silva J, Califano A. ScreenBEAM: a novel meta-analysis algorithm for functional genomics screens via Bayesian hierarchical modeling. Bioinformatics (Oxford, England) 2016 Jan; 32(2).
Putcha P, Yu J, Rodriguez-Barrueco R, Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, Quayle SN, Yang M, Castro V, Llobet-Navas D, Birnbaum D, Finetti P, Woodward WA, Bertucci F, Alpaugh ML, Califano A, Silva J. HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast cancer research : BCR 2015; 17(1).
Rodriguez-Barrueco R, Yu J, Saucedo-Cuevas LP, Olivan M, Llobet-Navas D, Putcha P, Castro V, Murga-Penas EM, Collazo-Lorduy A, Castillo-Martin M, Alvarez M, Cordon-Cardo C, Kalinsky K, Maurer M, Califano A, Silva JM. Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers. Genes & development 2015 Aug; 29(15).
Sanchez-Garcia F, Villagrasa P, Matsui J, Kotliar D, Castro V, Akavia UD, Chen BJ, Saucedo-Cuevas L, Rodriguez Barrueco R, Llobet-Navas D, Silva JM, Pe'er D. Integration of genomic data enables selective discovery of breast cancer drivers. Cell 2014 Dec; 159(6).
Llobet-Navas D, Rodríguez-Barrueco R, Castro V, Ugalde AP, Sumazin P, Jacob-Sendler D, Demircan B, Castillo-Martín M, Putcha P, Marshall N, Villagrasa P, Chan J, Sanchez-Garcia F, Pe'er D, Rabadán R, Iavarone A, Cordón-Cardó C, Califano A, López-Otín C, Ezhkova E, Silva JM. The miR-424(322)/503 cluster orchestrates remodeling of the epithelium in the involuting mammary gland. Genes & development 2014 Apr; 28(7).
Llobet-Navas D, Rodriguez-Barrueco R, de la Iglesia-Vicente J, Olivan M, Castro V, Saucedo-Cuevas L, Marshall N, Putcha P, Castillo-Martin M, Bardot E, Ezhkova E, Iavarone A, Cordon-Cardo C, Silva JM. The microRNA 424/503 cluster reduces CDC25A expression during cell cycle arrest imposed by transforming growth factor β in mammary epithelial cells. Molecular and cellular biology 2014 Dec; 34(23).
Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, Bonal DM, Charytonowicz E, Gladoun N, de la Iglesia-Vicente J, Petrylak DP, Benson MC, Silva JM, Cordon-Cardo C. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer cell 2012 Sep; 22(3).
Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer A, Llobet-Navas D, Rajbhandari P, Bansal M, Guarnieri P, Silva J, Califano A. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell 2011 Oct; 147(2).
Silva JM, Ezhkova E, Silva J, Heart S, Castillo M, Campos Y, Castro V, Bonilla F, Cordon-Cardo C, Muthuswamy SK, Powers S, Fuchs E, Hannon GJ. Cyfip1 is a putative invasion suppressor in epithelial cancers. Cell 2009 Jun; 137(6).
Silva JM, Marran K, Parker JS, Silva J, Golding M, Schlabach MR, Elledge SJ, Hannon GJ, Chang K. Profiling essential genes in human mammary cells by multiplex RNAi screening. Science (New York, N.Y.) 2008 Feb; 319(5863).
Silva JM, Li MZ, Chang K, Ge W, Golding MC, Rickles RJ, Siolas D, Hu G, Paddison PJ, Schlabach MR, Sheth N, Bradshaw J, Burchard J, Kulkarni A, Cavet G, Sachidanandam R, McCombie WR, Cleary MA, Elledge SJ, Hannon GJ. Second-generation shRNA libraries covering the mouse and human genomes. Nature genetics 2005 Nov; 37(11).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Silva during 2016 and/or 2017. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Acetylon Pharmaceuticals, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.